Health Canada approved XCOPRI™ (cenobamate tablets) for Paladin Labs, an Endo operating company. The medicine provides adjunctive therapy to manage partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
XCOPRI™ was developed by SK Biopharmaceuticals and SK life science. It is a small-molecule drug with dual mechanisms. In pre-clinical studies, XCOPRI™ has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel.
XCOPRI™ is currently marketed in the US as XCOPRI® and Europe under the trademark ONTOZRY®.